The big news
On October 30, 2026, the Department of Health and Human Services published its peptide policy in the Federal Register. This is the plan we have been tracking since it went to the White House in mid October.
The short version: HHS says it will not go after state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides, as long as they follow a list of quality rules.
The six peptides
BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.
That is both halves of the Wolverine stack, plus KPV from the KLOW blend. For years these have mostly been sold online as "research use only." Now there is a prescription route through a real pharmacy.
Why HHS did it
In its own words, HHS wants to steer people away from research-use-only peptides from foreign manufacturers, which it says pose a safety risk, and give patients "a more controlled alternative."
HHS also said the evidence has moved since FDA staff first reviewed these peptides. For BPC-157 and TB-500, it pointed to documented human use and new lot-level test certificates from FDA-registered facilities.
How the pharmacy lane works
You still need a prescription written for you. The pharmacy has to buy the raw peptide from an FDA-registered manufacturer, with a certificate of analysis showing identity, purity, and tests for things like endotoxins, heavy metals and microbes.
Each product can contain only one peptide. So a pharmacy cannot make a premixed Wolverine blend under this policy. BPC-157 and TB-500 would come as separate products.
The policy also sets which forms are covered. BPC-157 can be injected, taken by mouth or used on the skin. TB-500 is injection only. KPV is oral or topical, and Semax is a nasal spray.
Labels must say "This is a compounded drug product. Not for resale." Pharmacies also have to report serious side effects to FDA.
What is next
Public comments are open on regulations.gov, docket HHS-OASH-2026-0496, for two weeks after publication. Law firm Foley & Lardner puts the deadline at November 13, 2026.
FDA says future rulemaking may add some or all of these peptides to the official pharmacy ingredient list. That would make it more permanent.
The fine print
This is not FDA approval. Compounded drugs are not reviewed by FDA for safety or effectiveness, and the policy says so plainly.
It is also temporary and non-binding. HHS says it can pull back on any peptide if a safety signal or quality problem shows up. FDA's own scientists had recommended against listing BPC-157 and TB-500, and a drug safety group has petitioned to block this.
GHK-Cu, the copper peptide in GLOW and KLOW, is not on the list. Neither are retatrutide or CJC-1295 and ipamorelin.
This is education, not medical advice. If you are curious, talk to a licensed clinician who can order labs and keep an eye on how you respond.


